Karamvir Yadav, Medical Oncologist in Jaipur, India, shared posts on X:
“Breast cancer article conveying ‘Locally recurrent, Globally at Risk’
We call it ‘locoregional recurrence’…
But biologically, is it already systemic failure in disguise? Are we just late in escalation?”
Title: Randomized Phase III Trial for Evaluating the Efficacy of Adjuvant Abemaciclib in Patients With Locoregional Recurrence of Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: JCOG2313, AURA Trial
Authors: Yukinori Ozaki, Noriko Mitome, Emi Tokuda, Shinsuke Sasada, Akihiko Shimomura, Keita Sasaki, Riku Kajikawa, Chikako Funasaka, Atsushi Yoshida, Shin Takayama, Toshiyuki Ishiba, Takehiko Sakai, Yasuaki Sagara, Hideo Shigematsu, Kazuki Sudo, Kaori Terata, Yoichi Naito, Tomomi Fujisawa, Shigehira Saji, Hiroji Iwata, Fumikata Hara, Tadahiko Shien
Read the Full Article.
HER2 Heterogeneity in Breast Cancer May Explain Why Some Tumors Escape T-DXd
